Skip to main content


Fig. 3 | Molecular Neurodegeneration

Fig. 3

From: Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Fig. 3

a “Alanine scanning” showed that CDR grafting did not affect the epitope specificity. Armanezumab recognized epitope PRQEF comprising 4–8 amino acids of tau2–18 peptide. Inhibition of binding of Armanezumab to Tau2–18 by peptides with alanine substitution in competition ELISA. The half maximal inhibitory concentration (IC50) for each peptide is shown in Table. b Armanezumab recognized (i) full-length recombinant tau protein, but not tau that lacks aa 2–18 (ΔTau2-18), lanes 1–2 and (ii) aggregated forms of tau in brain homogenates from AD cases (Braak stage VI), lanes 3–7. Lane 1: ΔTau2-18; lane 2: Full-length tau; lane 3: control brain 1; lane 4: control brain 2; lane 5: AD brain 1; lane 6: AD brain 2; lane 7: AD brain 3. HT7 recognizing total tau and TNT-1 specific to N-terminus of tau were used as positive controls

Back to article page